CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
Email ID: complianceofficer@concordbiotech.com

August 01, 2026

To	To
The Manager, Listing Department	General Manager, Listing Department
National Stock Exchange of India Limited	**BSE Limited**
Plot No. C/1 G Block,	Phiroze Jeejeebhoy Towers,
Bandra-Kurla Complex, Bandra (East),	Dalal Street,
Mumbai -400 051	Mumbai – 400 001
Symbol: CONCORDBIO	Scrip Code: 543960

Sub.: Investor's Presentation on unaudited Standalone and Consolidated Financial Results for the first Quarter ended on June 30, 2026

Dear Sir/Ma'am,

Pursuant to Regulation 30 and Schedule III Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, "INVESTOR'S PRESENTATION" on unaudited Standalone and Consolidated Financial Results for the first Quarter ended on June 30, 2026 is enclosed.

Kindly take the above on records.

Thanking you,

For Concord Biotech Limited

Paritosh Trivedi
Digitally signed by Paritosh Trivedi
Date: 2026.08.01 18:33:01 +05'30'

Paritosh Trivedi
Company Secretary and Compliance Officer
ACS 63623

Encl: As above

CONCORD BIOTECH

CREATING ENDURING VALUE

Investor Presentation – August 2026

Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Concord Biotech Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness

Q1FY27 Key Financial Highlights

Q1FY27 Key Highlights

Broad based Growth
- Witnessed broad based growth across **All Product Categories**
- Growth across geographies with **Exports growing by ~46% for Q1FY27 (Y-o-Y)**

Wallet Share Growth & Customer Acquisition
- **Increase in wallet share** among existing customer along with **Addition of New Products** in existing customers
- Increase in customer base with **advanced discussions with large customers**

Robust Product Pipeline
- **Robust product pipeline** across product categories with target to **launch 2-3 products** every year

USFDA approval's for ANDA's
- Approval from USFDA for its ANDA for **Mycophenolate Mofetil & Tofacitinib Tablets**

Product Commercialization at Stellon Biotech
- Started **Commercial Operations & Sales** at Stellon Biotech

Injectable Ramp Up
- **Customer engagement at advanced levels**

Strengthening of Global Approvals
- **ANVISA inspection** conducted by the Brazilian Health Regulatory Agency at manufacturing facility in Limbasi
- Completed inspection by the **Pharmacy and Poisons Board (PPB)** from Kenya and the **National Drug Authority (NDA)** from Uganda at Unit-II formulation facility

EcoVadis Silver Medal – Sustainability Rating
- Received Silver medal from EcoVadis **placing Concord among the top 15% companies** assessed globally

Q1FY27 Consolidated Financial Highlights













EBIDTA margins (excluding impact of Injectable Facility & Expenses related to Stellon Biotech)

stood at **37%** for Q1FY27

Q1FY27 Segment wise Revenue Split

API Revenue (Rs. in Crs)



Formulation Revenue (Rs. in Crs)



Total Revenue (Rs. in Crs)



Domestic Revenue (Rs. in Crs)



Exports Revenue (Rs. in Crs)



Total Revenue (Rs. in Crs)



Management Commentary

Ankur Vaid

Joint Managing Director &
Chief Executive Officer

Commenting on the Q1 FY27 performance of the company Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer for Concord Biotech Limited said,

*"We are pleased to report a strong **revenue growth of 26% year-on-year** in Q1FY27, driven by broad-based performance across product categories and geographies. Export revenue **grew by an impressive 46% year-on-year,** reflecting our strong capabilities in delivering globally compliant products to regulated and semi-regulated markets.*

*During Q1FY27, we witnessed increased business from existing customers, **resulting in a higher wallet share and reinforcing our leadership** in niche and complex fermentation-based molecules. We also **expanded our customer base and product portfolio** with the addition of new customers and products, strengthening our growth pipeline and supporting sustained revenue momentum in the coming quarters.*

*On the regulatory front, we successfully completed **inspection by ANVISA** at our Limbasi facility, as well as **inspections by the Pharmacy and Poisons Board (PPB)** of Kenya and the **National Drug Authority (NDA)** of Uganda at our Unit-II formulation facility. These successful inspections further strengthen our regulatory credentials and enhance our readiness to serve global markets.*

Backed by the world's largest portfolio of fermentation-based products, best-in-class regulatory compliance, niche manufacturing capabilities, significant capacity, and a robust pipeline of new launches, we are confident of consistently outperforming industry growth, increasing wallet share, and strengthening our leadership position.

The Company remains focused on delivering sustainable long-term growth, supported by its compliance track record, differentiated product portfolio, and expanding customer relationships."

Q1FY27 Consolidated Profit & Loss Account

Profit and Loss (Rs. in Crs)	Q1FY27	Q1FY26	YoY
Revenue from Operations	**257**	**204**	**26.2%**
Cost of Goods Sold	54	45	
Gross Profit	**203**	**159**	**27.9%**
Gross Profit Margin	**78.9%**	**77.9%**	**100 bps**
Employee Cost	44	38	
Other Expenses	77	60	
EBITDA	**82**	**61**	**34.2%**
EBITDA Margin	**32.0%**	**30.1%**	**190 bps**
Depreciation	18	18	
Other Income	13	14	
EBIT	**77**	**57**	**34.6%**
Finance Cost	0	0	
Share in Profit/(loss) in JV and Associates	1	1	
Profit before Tax	**78**	**59**	**33.4%**
Tax	21	15	
PAT	**58**	**44**	**31.0%**
PAT Margin %	**22.4%**	**21.6%**	**80 bps**

Formulation Facility
Valthera, Ahmedabad, India

API Facility
Dholka, Ahmedabad, India

API Facility
Limbasi, Ahmedabad, India

Company Overview

Concord Biotech at a Glance

Concord Biotech Limited is a R&D driven biopharma Company that manufactures
Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.

Key Highlights

Portfolio spanning
30+
Fermentation APIs

150+
Drug Master Files (DMFs) filed globally

180+
Approved formulation products across markets

Fermentation capacity of
1,250m^3

7
ANDAs approved for products from our facilities

Overall formulation capacity of
869Mn – OSD (incl. Softgel)
13Mn – Liquid Vials
12Mn – Dry Filling Power
2,200 kgs – Bulk Sterile Lyophilized

Leading & Prominent Player in Fermentation & Biotechnology

World Leadership Position in Niche Fermentation based API

Expertise in Fermentation Technology

- ✓ **Expertise in fermentation**-based API manufacturing with high entry barriers
- ✓ One of the few global players **delivering consistently** in this specialized segment
- ✓ Built one of the **largest fermentation capacities globally**

Continuous Investment in R&D Driven Innovation

- ✓ **Strong focus on R&D** & State-of-the-art R&D facilities.
- ✓ Dedicated **team of scientists**.
- ✓ **Commitment to innovation** enables us to stay ahead of market trends.
- ✓ **Robust pipeline** for addition **of new products** to meet evolving market demands

Upholding the Highest Standards of Quality and Compliance

- ✓ **World-class infrastructure** adhering to global quality benchmark
- ✓ Facilities inspected by **USFDA, EU GMP, WHO, and PMDA, Japan**
- ✓ Presence **in over 70 countries,** including regulated markets

Driven by Expertise and Consistent Performance

- ✓ **Visionary leadership** driving consistent growth and global expansion
- ✓ Evolved from single-product to **multi-product company**
- ✓ Focus on fermentation, research, manufacturing, and compliance
- ✓ Positioned for **sustained leadership through innovation**

Driving Innovation Through Our Expertise

Mission Focus

Dedicated to deliver high-quality product that enhance human health, driven by innovation and customer centricity, fostering partnerships that make a meaningful impact

Visionary Leadership

Led by industry veterans. Our strategic decisions help us navigate challenges and drive sustained growth. This positions us as a trusted industry leader, committed to shaping a healthier tomorrow

Regulatory Compliance

Rigorous adherence to regulatory standards is integral to our operations, ensuring product integrity and customer trust, bolstering our reputation as a reliable partner in healthcare



Fermentation Expertise

Through our strong fermentation capabilities, we produce high-quality APIs, setting us apart in biotechnology and ensuring superior efficacy in medicines

Diversified Portfolio

We offer full baskets of immunosuppressants in addition to our products in oncology and anti infectives making total count of 30+ fermentation-based API's. This helps in ensuring resilience against market fluctuations and meeting diverse pharmaceutical needs effectively

Commitment to Innovation

Our heavy investment in R&D drives continuous process optimization, new product development, and industry leadership, fueling breakthroughs that shape the future of healthcare

API Business Overview

API Overview

One of the **leading global** developers and manufacturers of **Fermentation-based APIs**

Focus on **Niche Fermentation API's** with **backward integration** to Key Starting Material

Diversified Product Portfolio of API's including **Immuno-suppressant, Oncology, Anti-Infectives & Anti-Fungal**

Key Products

Immunosuppressant
- Tacrolimus
- Mycophenolate Mofetil
- Mycophenolate Sodium
- Cyclosporine
- Sirolimus
- Pimecrolimus
- Everolimus Premix 2%
- Voclosporin

Oncology
- Temsirolimus
- Everolimus
- Romidepsin
- Mitomycin
- Dactinomycin
- Staurosporin
- Midostaurne
- Everolimus Premix 9.09%

Antibacterial
- Mupirocin
- Mupirocin Calcium
- Polymyxin B Sulfate
- Teicoplanin
- Vancomycin Hydrochloride
- Fidaxomicin

Antifungal
- Anidulafungin
- Capspofungin Acetate
- Micafungin Sodium
- Amphotericin B
- Nystatin

`Others
- Lovastatin
- Pravastatin Sodium
- Enzymes

FY26 – **Rs~ 829** Crores Revenue

FY26 – **79%** Revenue Split

30+ Fermentation APIs

Formulation Business Overview

Formulation Overview

Commercialization of Formulations business in 2016 to capitalize on the **benefits of backward integration**

Operate through **B2B model** across regulated and emerging markets
For India Market, operate via **B2B & B2C model**

Oral Solid Dosages (tablets, capsules, softgel and oral suspension)
Injectables (Liquid Vials, Dry Powder Filling, Bulk Sterile Lyophilized)

Key Products

Antifungal

CRITICAL CARE

- Amfoterol™
- Anicord™
- Caspocon™
- Micacord™
- Vorixia™
- Picocord GR™
- Isacrest™

Antibiotics

CRITICAL CARE

- Dapute ™
- Fosutrac ™
- Pobix ™
- Teicocord ™
- Vanogard ™
- Cricolist ™
- Avycord ™
- Mepecon ™
- Mepecon
- Minocrit ™
- Tigicon ™
- Primataz ™
- Muprevent ™
- Clarinazest ™
- NextMatch ™

Plasma Products

CRITICAL CARE

- Gamacon ™
- Obulin ™

RHEUMATOLOGY

- Conimab
- Gammacord

Transplant & Immuno

NEPHROLOGY

- Tacrocord
- Mofecon
- Evercon
- Conimune ME
- Cyclograf
- Valocon
- Conimab

Chronic Kidney Disease

NEPHROLOGY

- Darbecon
- Epocord
- Sevecord
- Coniron
- Cinacet
- Valolog
- Injecarb
- Upshield
- Milipro
- Nabosis
- Kalcord
- Picatol
- Kanilev
- Lavits

Immunology

RHEUMATOLOGY

- Adacord
- Arthimide 1
- Arthimide 2
- Conimab 1
- Conimab 2
- Conimmune 25
- Mabdeno
- Cyclograp
- Mofecon 250
- Tacrocord 0.25
- Tofajoint ER
- Tofajoint
- Unuric 40
- Pricroda

FY26 – **Rs ˜ 226** Crores Revenue

FY26 – **21%** Revenue Split

180+ Approved Products

Trusted CDMO partner for Fermentation & Semi-Synthetic API's

CDMO Overview

Provide **contract research and manufacturing services** for developing APIs and formulations.

Prioritizes innovation, **backed by a DSIR-certified R&D facility** with a team of 180+ people

Expertise in fermentation technology and **strong R&D infrastructure** enable us to undertake complex projects and deliver **high-quality outcomes**

Key Strengths & Opportunities

- **Advanced fermentation capabilities**, expertise in strain isolation and enhancement, and scalable processes
- Facilitates **smooth transitions from lab research to full-scale production**
- **Specializes in Contract Research & Manufacturing,** with a focus on fermentation and semi-synthesis
- **Ample capacities** with necessary regulatory approvals **to ensure smooth & consistent supply**

Services Include

- **Strain Improvement**
- **Media Optimization**
- **Process Development**
- **Downstream Processing**

Pushing Boundaries through Manufacturing Capabilities

Unit I (API) – Dholka, Gujarat

- **FY2000** Operations commenced
- **1,12,302 sq.m.** Spread across
- **450 m^3** Installed capacity

Unit II (Formulations) – Valthera, Gujarat

- **FY2016** Operations commenced
- **94,826 sq.m.** Spread across
- **869Mn Units** Installed capacity

Unit III (API) – Limbasi, Gujarat

- **FY2021** Operations commenced
- **5,96,309 sq.m.** Spread across
- **800 m^3** Installed capacity

Unit IV (Injectables) – Valthera, Gujarat

- **FY2025** Operations commenced
- **36,441 sq.m.** Spread across
- Installed capacity of **13Mn** Liquid Vials, **12Mn** Dry Power Filling & **2,200** Kgs Bulk Sterile Lyophilized

Pioneering R&D Capabilities

187

R&D Employee Strength

12/7

Approved ANDA/ Finished Products

> 150

API DMFs

22+

Non-Infringing Processes

Spends as % of Sales				
3.6%	**3.5%**	**2.2%**	**2.3%**	**2.8%**



Robust pipeline of **more than 10 products** across different therapeutic segments of Oncology, Anti-Infectives & Anti-Fungal

R&D Initiatives:

- Cost Improvement
- New Product Development
- Process Improvement
- Technology Transfer
- Scale-Up Initiatives
- Enhancement of Backward Integration

State-of-the-Art Facilities: Where Ideas Materialise

API R&D Lab

- Specialized capabilities for isolation of strains, mutation, and passive selection of microbial strains, as well as strain improvement processes.
- Our R&D strengths enable us to drive innovation and develop new active pharmaceutical ingredients efficiently
- Equipped with fermenters and a pilot plant facility, allowing us to seamlessly scale up fermentation processes from lab scale to commercial production scale.

Our integrated R&D capabilities across API and formulations development allow us to bring new and innovative pharmaceutical products to the market effectively.

Formulations R&D Lab

- Focus on formulation development leveraging advanced analytical capabilities.
- R&D team works closely with our API experts to ensure our products meet the highest standards of quality and efficacy while providing optimal drug delivery and patient convenience

DMF Fillings Across Geographies

	Molecules	US	EU	Canada	Japan	China
Immuno-Suppressants	Tacrolimus	✓	✓	✓	✓	✓
	Mycophenolate Mofetil	✓	✓	✓	✓	✓
	Mycophenolate Sodium	✓	✓	✓		✓
	Cyclosporine	✓	✓	✓	✓	✓
	Sirolimus	✓	✓	✓	✓	
	Pimecrolimus	✓				
	Voclosporin	✓				
Oncology	Temsirolimus	✓	✓			
	Everolimus	✓	✓	✓	✓	
	Romidepsin	✓				✓
	Mitomycin	✓	✓	✓		
	Dactinomycin	✓				
	Midostaurin	✓				
Anti-Bacterial	Mupirocin	✓	✓	✓		✓
	Nystatin	✓	✓			
	Mupirocin Calcium	✓	✓	✓		
	Vancomycin Hydrochloride	✓	✓			
Others	Lovastatin	✓	✓			
	Pravastatin Sodium	✓	✓			

Wide Range of Formulation Product Portfolio for Overseas Markets

Regulated Markets

Product Name	ANDA Approval
Mycophenolate Mofetil Capsules	✓
Mycophenolic Acid DR Tablets USP	✓
Mycophenolate Mofetil Tablets	✓
Mycophenolate Mofetil Suspension	✓
Tacrolimus Capsules USP	✓
Teriflunomide Tablets	✓
Tofacitinib Tablets	✓

Emerging Markets

Product Name
Mycophenolate Mofetil Capsules
Mycophenolate Mofetil Tablets
Mycophenolate Mofetil Suspension
Mycophenolate Sodium 180mg Tablets
Mycophenolate Sodium 360mg Tablets
Tacrolimus 0.5 / 1 / 5mg Capsules
Teriflunomide 7 / 14mg Tablets
Tofacitinib 5 / 10mg Tablets

Diversified Customer Base

70+
Countries

300+
Customers

Reducing Customer Concentration % Contribution from Top 10 Customers



Worldwide Presence

Tailored Distribution Models

Collaborative Partnerships

Paving the Way for Sustainability

Our Vision for Sustainability

- Sustainable Manufacturing
- Global Green Leadership
- Environmental Conservation

The Path of Sustainability

- Research & Development
- Efficient Resource Management
- Constant Improvement & Adaptation

SILVER | Top 15%
ecovadis
Sustainability Rating
MAY 2026

valid through **May 2027**

Awarded Silver Medal by EcoVadis

CONCORD BIOTECH LTD

CONCORD BIOTECH LTD has earned a **Silver Medal**, a recognition awarded to the **Top 15%** of companies assessed by **EcoVadis** in the 12 months prior to the medal issue date. It reflects the quality of the company's sustainability management system and demonstrates a commitment to promoting transparency throughout the value chain. Learn more about EcoVadis Medals & Badges.

EcoVadis is recognized globally for trusted business sustainability ratings.

Link

Our Initiatives on Sustainability

- ✓ Increasing use of Renewable energy
- ✓ Corporate Social Responsibility
- ✓ Driving towards sustainable future
- ✓ Reduced ecological harm
- ✓ Improved water quality

BUREAU VERITAS 1828

Received

ISO-14001:2015 & ISO-45001:2018

Certifications

Key Business Differentiators

End-to-End Expertise in Complex Fermentation Value Chain

01

Leadership Position

Leadership position for select molecules in global markets

02

Over 2 Decades

Experience in the industry with a demonstrated track record of developing niche and complex molecules

03

1,250 M^3

Fermentation Capacity across two API facilities

04

30+ Fermented based API's

One of leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants oncology and Anti-infectives in terms of market share

Overview of Integrated Platform

- R&D
- Patents
- Key Starting Material
- API Manufacturing
- Formulations
- Marketing & Distribution

Constructing Formidable Barriers to Entry

Significant Entry Barriers → **Complex Process & Technical Expertise** + **Capital Intensive Infrastructural Requirements** + **Operational Requirements (large scale fermenters)** + **Long gestation Period**

Complex technical capabilities, difficulties in scaling up operations and substantial capital investment required have resulted in **significant barriers to entry** in the fermentation-based API space

Concord Biotech's Strong Capabilities

01 Portfolio Across a **Wide Range of Therapeutic Areas**

02 **Scaled manufacturing facilities** with a consistent **regulatory compliance** track record

03 **Flexible** plant configuration

04 **Backward Integrated** to KSM level

05 **Regulatory Approvals** for global markets

06 **Commercialized** a wide spectrum of fermentation-based APIs

Key Growth Drivers

CONCORD BIOTECH

Key Growth Drivers

01 API Business

- Expanding API Portfolio
- Marketing existing APIs to new customers
- Increasing wallet share with existing customers

02 Formulations Business

- Expanding portfolio through own development & in-licensing
- Launching new dosage forms including injectables
- Expanding geographic reach in India, EMs and the US

03 CDMO Business

- Leverage established fermentation platform, strong R&D, manufacturing and relationships with global players
- Trusted CDMO partner for Fermentation & Semi-Synthetic API's

04 Operational Efficiencies

- Utilization & Capex to drive future growth
- Focus on process efficiency, operating leverage and product mix

For further Information, please contact

Company:

CONCORD BIOTECH

Concord Biotech Limited

CIN: L24230GJ1984PLC007440
Mr. Raviraj Karia – Chief Financial Officer
ravirajkaria@concordbiotech.com

www.concordbiotech.com

Investor Relations Advisor:

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.
CIN - U74140MH2010PTC204285
Mr. Sagar Shroff / Mr. Vatsal Shah
sagar.shroff@sgapl.net
+91 98205 19303
www.sgapl.net